Synthetic lethality exploitation: Preclinical in vivo models of BRCA1/2-deficient cancers are essential to validate APE1/APE2 inhibition as a therapeutic window, define biomarkers of sensitivity, and identify resistance mechanisms. This evidence concerns the gene APEX1 and cancer.